NCT07699328 VRN-11 EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07699328 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.

MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.

Why NCT07699328 is a hot trial to watch

EGFR-mutated non-small Cell Lung Cancer is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07699328 is notable because it evaluates VRN-11 in a Phase 1/2 design sponsored by Voronoi, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.

Trial landscape snapshot

Protocol design and endpoint interpretation

This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitumor activity in patients with EGFR-mutant NSCLC, including patients with acquired resistance following EGFR tyrosine kinase inhibitor therapy.

Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment. Planned enrollment of [object Object] participants across Canada, South Korea, Singapore, Hong Kong, Taiwan Province, Malaysia, Thailand, France, Australia, Spain shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Estimate of Maximum Tolerated Dose (MTD) of VRN110755 (28 days) — This will be based on dose-limiting toxicities (DLTs) observed during the DLT evaluation period.
• Number of participants with dose-limiting toxicities (DLTs) following treatment with VRN110755 (28 days) — Dose-limiting toxicities will be assessed according to protocol-defined DLT criteria during the DLT evaluation period.
• Number of participants experiencing treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation (From first dose until end of study (up to approximately 6 years))
• Number of participants with changes in vital signs from baseline following treatment with VRN110755 (From baseline through End of Treatment (up to approximately 6 years)) — Vital signs include blood pressure, pulse rate, respiratory rate, body temperature, and oxygen saturation.

Readout outlook and evidence gap

The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.

Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset MCP profile: VRN-11 is indexed as Small molecule drug, with target EGFR C797S x EGFR L858R x EGFR T790M x EGFR-Ex19del, mechanism EGFR C797S inhibitors, EGFR T790M inhibitors, EGFR exon 19 deletion inhibitors, and global highest development status Phase 1/2.

Company & Deal Intelligence MCP profile: Voronoi, Inc. is resolved to a normalized organization record in South Korea. The organization workflow adds identity, location, portfolio and partnering context where available.

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.

Bottom line

NCT07699328 provides a focused lens on EGFR-mutated non-small Cell Lung Cancer development. Its value will be determined by whether VRN-11 can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.